The traditional DNMT inhibitors, especially 5-azacitidine and decitabine, have shown great clinical efficacy in hematologic malignancies, but lacked efficacy when used alongside immunotherapy in BLCA. This evidence concerns the gene DNMT1 and hematologic disorder.